Press Release: Curetis to Publish its Annual Results 2016 on April 12, 2017

Curetis / Curetis to Publish its Annual Results 2016 on April 12, 2017 . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the content of this announcement.

Curetis to Publish its Annual Results 2016 on April 12, 2017

- Company to host earnings conference call and webcast

Amsterdam, the Netherlands and Holzgerlingen, Germany, April 4, 2017 -- Curetis N.V. (the "Company" and, together with Curetis GmbH, "Curetis"), a developer of next-level molecular diagnostic solutions, today announced that it will publish its full-year 2016 financial results on April 12, 2017. In addition, the Company will host a public earnings conference call and webcast on April 12, 2017, at 03:00 pm CET / 09:00am EST to present the financial results of 2016, highlight the most important events and provide an outlook for 2017.

The conference call will be supplemented by a presentation which can be accessed during the call at http://www.curetis.com/en/investors/financial-reports-and-conferences.html.

For participating in the earnings call conference please access the presentation at http://www.audio-webcast.com/ using the passcode curetis0417.

To access the call, please dial the following numbers using the passcode 93120684#

Belgium: +32 11500307

Germany: +49 69222229043

Netherlands: +31 107137273

UK: +44 2030092452

U.S.: +1 855 4027766

Further country-specific dial-in numbers can be found at http://events.arkadin.com/ev/docs/International Access Numbers_ UKFELBRI1_SU7.pdf

The full annual financial report 2016 will be available as of April 12, 2017, at http://www.curetis.com/en/investors/financial-reports-and-conferences.html

The live webcast and a replay will be available at http://curetis120417-live.audio-webcast.com.

Disclaimer

CAUTION - Investigational device. Limited by Federal (or United States) law to investigational use. The information contained in this communication does not constitute nor imply an offer to sell or transfer any product, and no product based on the Curetis Unyvero technology is currently available for sale in the United States of America or Canada. The analytical and clinical performance characteristics of any Curetis Unyvero product which may be sold at some future point in time in the U.S. have not yet been established.

###

About Curetis

Founded in 2007, Curetis is a molecular diagnostics company which focuses on the development and commercialization of reliable, fast and cost-effective products for diagnosing severe infectious diseases. The diagnostic solutions of Curetis enable rapid multi-parameter pathogen and antibiotic resistance marker detection in only a few hours, a process that today can take up to days or even weeks with other techniques.

To date, Curetis has raised EUR 44.3 million in an IPO on Euronext Amsterdam and Euronext Brussels and private equity funds of over EUR 63.5 million. Furthermore, Curetis has entered into a debt financing facility with EIB for up to EUR 25 million. The company is based in Holzgerlingen near Stuttgart, Germany. Curetis collaborates with Heraeus Medical, pharmaceutical companies, and has entered into several international distribution agreements covering many countries across Europe, the Middle East and Asia.

For further information, please visit www.curetis.com.

Legal Disclaimer

This document constitutes neither an offer to buy nor to subscribe securities and neither this document nor any part of it should form the basis of any investment decision in Curetis.

The information contained in this press release has been carefully prepared. However, Curetis bears and assumes no liability of whatever kind for the correctness and completeness of the information provided herein. Curetis does not assume an obligation of whatever kind to update or correct information contained in this press release whether as a result of new information, future events or for other reasons.

This press release includes statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the use of forward-looking terminology, including the terms "believes", "estimates", "anticipates", "expects", "intends", "may", "will", or "should", and include statements Curetis makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. Curetis' actual results may differ materially from those predicted by the forward-looking statements. Curetis undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.

Contact details

Curetis AG

Max-Eyth-Str. 42

71088 Holzgerlingen, Germany

Tel. +49 7031 49195-10

pr@curetis.com or ir@curetis.com

www.curetis.com - www.unyvero.com

International Media & Investor Inquiries

akampion

Dr. Ludger Wess / Ines-Regina Buth

Managing Partners

info@akampion.com

Tel. +49 40 88 16 59 64

Tel. +49 30 23 63 27 68

U.S. Media & Investor Inquiries

The Ruth Group

Lee Roth

lroth@theruthgroup.com

Tel. +1 646 536 7012

20160404_Curetis_PR_EN: http://hugin.info/171382/R/2093418/791310.pdf Curetis_Logo http://hugin.info/171382/R/2093418/791312.jpg

This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Curetis via Globenewswire

--- End of Message ---

Curetis

Max-Eyth-Str. 42 Holzgerlingen Germany

Listed: Open Market (Freiverkehr) in Frankfurter Wertpapierbörse;

http://www.curetis.com/ (END) Dow Jones Newswires

   April 04, 2017 02:31 ET (06:31 GMT)- - 02 31 AM EDT 04-04-17